Prostate cancer biomarkers: Are we hitting the mark? - Wikidata - wikimedia - TriplyDB

Prostate cancer biomarkers: Are we hitting the mark?

Prostate cancer biomarkers: Are we hitting the mark?

http://www.wikidata.org/entity/Q28071654

about

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports.68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens.Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer.The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer Urinary markers aiding in the detection and risk stratification of prostate cancer Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence

P2860

Q41660235-BCBC9F9A-4350-4D2A-8B49-16FA45A6E859 Q41667232-3886EA8F-D66A-421A-9916-2E106FA101DE Q47094262-689594D7-21A9-4E7E-86AF-8CBF44543C73 Q47269407-AF979034-4CE7-48D7-ADA7-5409F7BAFDE4 Q48231387-4E846534-C1AE-4406-AF4C-2F5DB4FE2547 Q52679257-069EFED0-1085-4E82-96F2-3D484557C119 Q55042333-86E4D346-D9F2-4912-9993-394A6FCCDA1B Q57073785-C38248CC-6575-440D-A49F-D8D888FB7AA6 Q57107312-CB62289D-485A-4589-BA3D-4929F9465418 Q57107671-39FF8E79-8260-4485-BF95-3D39CCE59E86 Q58562073-5645B2B8-ABDF-4EFB-AE12-64BB843D61A4 Q58788279-9FB19AA8-1918-4BA7-AA8F-C4AB1B0ABB74

P2860

Prostate cancer biomarkers: Are we hitting the mark?

http://www.wikidata.org/entity/Q28071654

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Prostate cancer biomarkers: Are we hitting the mark?

@ast

Prostate cancer biomarkers: Are we hitting the mark?

@en

Prostate cancer biomarkers: Are we hitting the mark?

@nl

type

label

Prostate cancer biomarkers: Are we hitting the mark?

@ast

Prostate cancer biomarkers: Are we hitting the mark?

@en

Prostate cancer biomarkers: Are we hitting the mark?

@nl

prefLabel

Prostate cancer biomarkers: Are we hitting the mark?

@ast

Prostate cancer biomarkers: Are we hitting the mark?

@en

Prostate cancer biomarkers: Are we hitting the mark?

@nl

P1433

Q28071654-32ACA7A7-0C79-4B86-9498-9256A228E902

P1476

Q28071654-799A3F8C-EBFC-456F-8EA0-6FF927946BBD

P2093

Q28071654-13327CAC-9848-4E19-89F0-ACBE095FF497

Q28071654-13336552-110E-4D41-BD82-36CF3194E25C

Q28071654-A18AE7C7-0021-4E74-AB59-1C14015E39F7

Q28071654-B06C8216-110C-4932-B070-B1E8775AC4C3

Q28071654-CA6C42E7-146C-49A1-BA19-599C54F2C10A

Q28071654-D56EDA8B-C928-4E30-AB15-7E3E595357A0

Q28071654-D8D0A9A5-9D4F-4C62-A0C3-A8F03110C5AD

P2860

Q28071654-07F82A85-739E-4A9B-BAAB-04B8FB189B42

Q28071654-0B54B2A8-8573-4879-A0F2-4794C6C0B6ED

Q28071654-0D43ECC3-FA52-4D11-8699-7279D1496E75

Q28071654-13512AC8-38DA-4588-B150-AA23452D87D6

Q28071654-15EFA01C-D36B-4B25-B202-B3379DBFAA48

Q28071654-1644B636-CA43-42CD-BE05-16D956292542

Q28071654-307C395A-D58F-49B6-BDE5-8E03D5F08AA4

Q28071654-3804E474-EC28-47B3-BB42-00A39437E263

Q28071654-3C3A14B4-C4E8-4039-B80B-DB1B80991F4B

Q28071654-3F7F8F7A-0035-4CBC-A8F4-CD6EE9299254

P304

Q28071654-4B1FBA59-A4FD-4C36-A469-E9D6100D0611

P31

Q28071654-73661164-1543-412B-94F1-F1B81A30E276

P3181

Q28071654-A9B6BBC7-A27B-4947-AE44-2E406778429F

P356

Q28071654-FDB2A247-7F93-44B2-93B5-EFBA5D8FCB4B

P407

Q28071654-3071404E-042A-4851-B0C1-05FD61C0987E

P433

Q28071654-2C3E7F85-447B-4E5F-872A-69FF982BD395

P478

Q28071654-1F537505-0926-44C3-99B6-3F8ACAC4DB29

P577

Q28071654-E7857ADD-FFC4-4E99-8695-AFE365D283A6

P698

Q28071654-52E887AF-1903-4F9C-AB33-CF15B9A9A5C0

P921

Q28071654-EB6F40C0-290D-4A85-A073-3C17E739324F

P932

Q28071654-9F3950E9-7CA5-497B-8B98-51336AEAEE3D

P3181

P356

J.PRNIL.2016.07.002

P1433

Prostate international

P1476

Prostate cancer biomarkers: Are we hitting the mark?

@en

P2093

Daniel Christidis

http://www.w3.org/2001/XMLSchema#string

Ian Vela

http://www.w3.org/2001/XMLSchema#string

Marlon Perera

http://www.w3.org/2001/XMLSchema#string

Nathan Lawrentschuk

http://www.w3.org/2001/XMLSchema#string

Shannon McGrath

http://www.w3.org/2001/XMLSchema#string

Sung Kyu Hong

http://www.w3.org/2001/XMLSchema#string

Todd Manning

http://www.w3.org/2001/XMLSchema#string

P2860

PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

Cancer statistics, 2016

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies

Time trends and local variation in primary treatment of localized prostate cancer

Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

P304

130-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4222846

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.PRNIL.2016.07.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27995111

http://www.w3.org/2001/XMLSchema#string

P921

P932

5153438

http://www.w3.org/2001/XMLSchema#string